About us
Sonas Pharma was founded to bridge the gap between scientific innovation and patient need. We focus on translating cutting-edge endocannabinoid research into safe, effective treatments for epilepsy and metabolic disease. By combining scientific rigor with a strong clinical focus, we aim to deliver therapies that provide real, meaningful benefits to patients and their families.
Our leadership team combines deep scientific expertise, proven drug development success and decades of industry experience from leading institutions.
Our Story
Sonas Pharma was founded in Northern Ireland and focuses on developing endocannabinoid-based medicines for epilepsy and metabolic disease. We are dedicated to advancing innovative, science-led therapies that improve patients’ lives worldwide.
Our Vision
Sonas Pharma is a preclinical biotechnology company developing endocannabinoid-based therapies for epilepsy and metabolic disease.
Our vision is to build a leading endocannabinoid medicine company that delivers safe, effective, and accessible treatments for patients worldwide.
We are committed to scientific excellence, regulatory rigour, and patient-centered innovation as we advance our pipeline of novel therapies.